Kolexia
Plantier-Colcher Isabelle Hématologie
Plantier-Colcher Isabelle
Hématologie
Centre Hospitalier de Roubaix
Roubaix, France
58 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Leucémie-lymphome lymphoblastique à précurseurs B et T Chromosome Philadelphie Lymphomes Lymphome B Lymphome B diffus à grandes cellules Aberrations des chromosomes

Collaborateurs

Voir plus
Berthon Céline
Berthon Céline
Hôpital Huriez, Lille, France
Dervite-Vaussoue Isabelle
Dervite-Vaussoue Isabelle
Centre Hospitalier de Roubaix, Roubaix, France
Wemeau Mathieu
Wemeau Mathieu
Hôpital Huriez, Lille, France
Nibourel Olivier
Nibourel Olivier
Hôpital Albert Calmette, Lille, France

Industries

Voir plus
Novartis
8 collaboration(s)
Dernière en 2023
Abbvie
6 collaboration(s)
Dernière en 2023
Janssen
3 collaboration(s)
Dernière en 2023
Servier
1 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Nilotinib with or without cytarabine for Philadelphia positive acute lymphoblastic leukemia.
Blood   07 mars 2024
ALFA2101: An ALFA 2101 Multicenter Randomized Phase II Study: CPX-351 Versus Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
Essai Clinique (CHU Nice)   29 janvier 2024
Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim
Annual Meeting Abstracts 2022   15 novembre 2022
Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial
Blood   23 novembre 2021
The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study
Blood   23 novembre 2021
The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively.
Cancers   29 avril 2021
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
Leukemia   22 janvier 2021
Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively
Blood   05 novembre 2020
BIG-1: Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial
Essai Clinique (CHU Angers)   16 octobre 2020
Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk.
Haematologica   01 septembre 2020